Hester Biosciences Limited has informed the Exchange about Transcript
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences reported strong Q4 FY26 results with standalone revenue up 22% and PAT surging 174%. For the full year, while standalone revenue remained flat, PAT grew 64% with consolidated PAT nearly doubling. The Poultry Healthcare segment delivered exceptional performance (up 41% in Q4, 21% for FY26) driven by market penetration and expanded vaccine portfolio. The company received marketing and manufacturing licenses for H9N2 Avian Influenza vaccine. Animal Healthcare division faced tender delays but showed improvement in Q4 with 6.3 crore PPR doses supplied. Management emphasized operational discipline and cost optimization as key drivers of profitability improvement. The company reduced debt from INR 102 crores to INR 70 crores while commissioning new Fill-Finish and BSL-3 facilities.
Strong profitability improvement despite flat revenue signals successful cost control and operational efficiency. Management aims to sustain improved margins and targets returning to a balanced 50-50 revenue mix between Poultry and Animal Healthcare divisions. High receivables (INR 92 crores) and write-offs remain concerns to monitor.